Financial reports
10-K
2023 FY
Annual report
23 Feb 24
10-Q
2023 Q3
Quarterly report
27 Oct 23
10-Q
2023 Q2
Quarterly report
2 Aug 23
10-Q
2023 Q1
Quarterly report
2 May 23
10-K
2022 FY
Annual report
24 Feb 23
10-Q
2022 Q3
Quarterly report
1 Nov 22
10-Q
2022 Q2
Quarterly report
2 Aug 22
10-Q
2022 Q1
Quarterly report
3 May 22
10-K
2021 FY
Annual report
25 Feb 22
10-Q
2021 Q3
Quarterly report
29 Oct 21
Current reports
8-K
Federated Hermes, Inc. reports fourth quarter and full-year 2023 earnings
25 Jan 24
8-K
Departure of Directors or Certain Officers
15 Dec 23
8-K
Federated Hermes, Inc. reports third quarter 2023 earnings
26 Oct 23
8-K
Federated Hermes, Inc. reports second quarter 2023 earnings
27 Jul 23
8-K
Federated Hermes, Inc. reports first quarter 2023 earnings
27 Apr 23
8-K
Federated Hermes, Inc. reports fourth quarter and full-year 2022 earnings
26 Jan 23
8-K
Federated Hermes, Inc. reports third quarter 2022 earnings
27 Oct 22
8-K
Federated Hermes, Inc. reports second quarter 2022 earnings
28 Jul 22
8-K
Entry into a Material Definitive Agreement
18 Jul 22
8-K
Other Events
7 Jun 22
Registration and prospectus
S-8
Registration of securities for employees
10 Jan 22
S-8
Registration of securities for employees
30 Apr 18
S-8
Registration of securities for employees
2 May 11
S-8
Registration of securities for employees
27 Jul 06
S-8 POS
Registration of securities for employees (post-effective amendment)
17 May 01
S-8 POS
Registration of securities for employees (post-effective amendment)
17 May 01
425
Business combination disclosure
26 Jun 00
425
Business combination disclosure
26 Jun 00
425
Business combination disclosure
26 Jun 00
425
Business combination disclosure
26 Jun 00
Proxies
DEF 14C
Information statement
13 Mar 24
DEF 14C
Information statement
15 Mar 23
DEF 14C
Information statement
16 Mar 22
DEF 14C
Information statement
17 Dec 21
DEF 14C
Information statement
18 Mar 21
DEFA14C
Additional information
15 Apr 20
DEFA14C
Additional information
2 Apr 20
DEF 14C
Information statement
19 Mar 20
DEF 14C
Information statement
14 Mar 19
DEFR14C
Revised information
17 Apr 18
Other
UPLOAD
Letter from SEC
11 Feb 13
CORRESP
Correspondence with SEC
18 Jan 13
CORRESP
Correspondence with SEC
14 Jan 13
UPLOAD
Letter from SEC
31 Dec 12
UPLOAD
Letter from SEC
5 Dec 11
CORRESP
Correspondence with SEC
28 Nov 11
CORRESP
Correspondence with SEC
14 Nov 11
UPLOAD
Letter from SEC
7 Nov 11
UPLOAD
Letter from SEC
11 May 10
CORRESP
Correspondence with SEC
5 May 10
Ownership
SC 13D
Fusion Pharmaceuticals Inc.
25 Mar 24
SC 13G/A
VANGUARD GROUP INC
11 Mar 24
4
THOMAS R DONAHUE
7 Mar 24
4
Peter J Germain
7 Mar 24
4
Meter Stephen Van
7 Mar 24
4
Paul A Uhlman
7 Mar 24
4
Saker Anwar Nusseibeh
7 Mar 24
4
Richard A Novak
7 Mar 24
4
J CHRISTOPHER DONAHUE
7 Mar 24
4
Dolores D Dudiak
7 Mar 24